Sionna Therapeutics, Inc. (NASDAQ: SION) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 45.15M | Perf Week | -5.77% |
| Market Cap | 324.18M | Forward P/E | - | EPS next Y | -2.29 | Insider Trans | -7.54% | Shs Float | 26.61M | Perf Month | 20.88% |
| Enterprise Value | 120.18M | PEG | - | EPS next Q | -0.63 | Inst Own | - | Short Float | 16.15% | Perf Quarter | -80.45% |
| Income | -75.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 2.36 | Perf Half Y | -79.13% |
| Sales | 0.00 | P/B | 1.22 | EPS next Y | 7.52% | ROA | -34.38% | Short Interest | 4.30M | Perf YTD | -82.55% |
| Book/sh | 5.89 | P/C | 1.54 | EPS next 5Y | - | ROE | -32.94% | 52W High | 54.98 -86.94% | Perf Year | -69.14% |
| Cash/sh | 4.67 | P/FCF | - | EPS past 3/5Y | - | ROIC | -39.98% | 52W Low | 4.01 79.05% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 9.02% 8.59% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -55.71% | Oper. Margin | 0.00% | ATR (14) | 1.47 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 20.05 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 31.99 | Recom | 2.75 |
| Dividend Gr. 3/5Y | - | Current Ratio | 20.05 | EPS Q/Q | -60.98% | SMA20 | 7.09% | Beta | 1.10 | Target Price | 27.40 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | - | SMA50 | -70.14% | Rel Volume | 0.73 | Prev Close | 7.04 |
| Employees | 59 | LT Debt/Eq | 0.02 | Earnings | Nov 04 | SMA200 | -79.92% | Avg Volume | 2.01M | Price | 7.18 |
| IPO Date | Feb 07, 2025 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1.54% - | Net Debt/EBITDA | 0.59 | Volume | 1,476,052 | Change | 1.99% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-15-26 | Reiterated | Wedbush | Neutral | $5.00 → $6.00 |
| Aug-11-26 | Downgrade | Guggenheim | Buy → Neutral | |
| Aug-11-26 | Downgrade | Wedbush | Outperform → Neutral | $5.00 |
| Aug-10-26 | Reiterated | RBC Capital | Underperform | $24 → $5.00 |
| Aug-10-26 | Reiterated | Stifel Nicolaus | $7.00 | |
| Aug-10-26 | Downgrade | BTIG | Buy → Neutral | |
| Aug-07-26 | Reiterated | Guggenheim | Buy | |
| Aug-06-26 | Reiterated | Raymond James | ||
| May-20-26 | Downgrade | Freedom Broker | Buy → Hold | |
| May-18-26 | Reiterated | Stifel Nicolaus |
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | |
| Cost of Goods Sold Incl. D&A | 1 | 1 | 0 | — | |
| Gross Profit | -1 | -1 | 0 | — | |
| Selling, General and Administrative Excl. Other | 29 | 13 | 10 | — | |
| Research and Development | 60 | 57 | 41 | — | |
| Other Operating Expense | -1 | 0 | -1 | — | |
| Operating Income | -89 | -71 | -50 | — | |
| Interest Expense | 0 | 0 | 0 | — | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | 14 | 9 | 3 | — | |
| Net Income Before Taxes | -75 | -62 | -47 | — | |
| Income Taxes | 0 | 0 | 0 | — | |
| Consolidated Net Income | -75 | -62 | -47 | — | |
| Net Income From Continuing Operations | -75 | -62 | -47 | — | |
| Net Income | -75 | -62 | -47 | — | |
| EPS (Recurring) | -1.88 | -1.40 | -1.07 | — | |
| EPS (Basic, Before Extraordinaries) | -1.88 | -1.40 | -1.07 | — | |
| EPS (Diluted) | -1.88 | -1.40 | -1.07 | — | |
| EBITDA | -75 | -61 | -47 | — | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | |
| Gross Margin | — | — | — | — | |
| Operating Margin | — | — | — | — | |
| Net Margin | — | — | — | — | |
| Shares Outstanding | 40 | 44 | 44 | — | |
| Market Capitalization | 1,646 | — | — | — | |
| Operating Lease Expense | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director | Jul 07 '26 | Sale | 44.86 | 85,918 | 3,854,281 | 2,469,959 | Jul 09 |
| Thompson Peter A. | Director | Jul 07 '26 | Sale | 44.86 | 85,918 | 3,854,281 | 2,469,959 | Jul 09 |
| Fitzpatrick Jennifer | Chief Legal Officer | Jul 06 '26 | Option Exercise | 6.11 | 10,250 | 62,628 | 10,250 | Jul 07 |
| Fitzpatrick Jennifer | Chief Legal Officer | Jul 06 '26 | Sale | 43.60 | 10,250 | 446,862 | 0 | Jul 07 |
| ORBIMED ADVISORS LLC | Director | Jun 30 '26 | Sale | 45.50 | 115,844 | 5,270,902 | 2,555,877 | Jul 02 |
| Thompson Peter A. | Director | Jun 30 '26 | Sale | 45.50 | 115,844 | 5,270,902 | 2,555,877 | Jul 02 |
| Thompson Peter A. | Director | May 27 '26 | Sale | 44.49 | 101 | 4,493 | 2,671,721 | May 29 |
| ORBIMED ADVISORS LLC | Director | May 27 '26 | Sale | 44.49 | 101 | 4,493 | 2,671,721 | May 29 |
| Thompson Peter A. | Director | May 11 '26 | Sale | 46.22 | 184,639 | 8,534,015 | 2,671,822 | May 11 |
| ORBIMED ADVISORS LLC | Director | May 11 '26 | Sale | 46.22 | 184,639 | 8,534,015 | 2,671,822 | May 11 |
| ORBIMED ADVISORS LLC | Director | May 08 '26 | Sale | 44.58 | 59,767 | 2,664,413 | 2,856,461 | May 11 |
| Thompson Peter A. | Director | May 08 '26 | Sale | 44.58 | 59,767 | 2,664,413 | 2,856,461 | May 11 |
| ORBIMED ADVISORS LLC | Director | May 07 '26 | Sale | 44.61 | 48,546 | 2,165,637 | 2,916,228 | May 11 |
| Thompson Peter A. | Director | May 07 '26 | Sale | 44.61 | 48,546 | 2,165,637 | 2,916,228 | May 11 |
| Thompson Peter A. | Director | Apr 18 '26 | Sale | 44.52 | 2,948 | 131,245 | 2,964,774 | Apr 21 |